Yu-Chih Shen1, Chien-Chen Hung2
1Department of Psychiatry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Intranasal esketamine (Spravato®) showed promising results for a patient with treatment-resistant depression (TRD) and a history of poor response to electroconvulsive therapy (ECT). The treatment improved depression scores and resolved suicidal ideation with manageable side effects.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background: